Peijia's TaurusTrio TAV system wins NMPA approval, revolutionizing severe AR treatment with Jenavalve's locator technology.

The EARLY TAVR (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) trial results demonstrate that early transcatheter aortic valve implantation (TAVI) ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Many people around the age of 60 experience a decline in physical performance due to aortic valve stenosis. In this condition, the heart valve, which is located between the left ventricle and the ...

PARIS, France—There is more than a twofold greater risk of death, and a significantly increased risk of major adverse cardiac events, over nearly 2 years of follow-up when patients with a bicuspid ...

Researchers have developed cutting-edge MRI technology to diagnose a common heart problem more quickly and accurately than ever before. Aortic stenosis is a progressive and potentially fatal condition ...

Asymptomatic patients with severe aortic stenosis can now undergo transcatheter aortic valve replacement, thanks to the US Food and Drug Administration’s approval of the new indication for the balloon ...

Please provide your email address to receive an email when new articles are posted on . A first-of-its-kind therapy successfully slowed plaque progression in patients with aortic stenosis. Ataciguat ...

Having any sleep disorder was independently linked to a higher likelihood for developing aortic stenosis, although dyslipidemia appeared to be an important mediator of the risk Data from the TriNetX ...

A recent editorial claimed that “it’s time to act” in asymptomatic patients with severe aortic stenosis (AS). The expert authors, including eminent cardiologist Eugene Braunwald, MD, proposed that the ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.